CANCER:

Endocrine Cancer

No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	mitotane Sensitive: A1 - Approval	mitotane Sensitive: A1 - Approval
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive: A2 - Guideline	cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	cisplatin Sensitive: A2 - Guideline	cisplatin Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	cisplatin + etoposide IV Sensitive: A2 - Guideline	cisplatin + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline	cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	carboplatin + etoposide IV + mitotane Sensitive: A2 - Guideline	carboplatin + etoposide IV + mitotane Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline	carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	carboplatin + etoposide IV Sensitive: A2 - Guideline	carboplatin + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline	carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	cisplatin + etoposide IV + mitotane Sensitive: A2 - Guideline	cisplatin + etoposide IV + mitotane Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline	cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	streptozocin Sensitive: A2 - Guideline	streptozocin Sensitive: A2 - Guideline
No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	No biomarker No biomarker	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	mitotane + streptozocin Sensitive: A2 - Guideline	mitotane + streptozocin Sensitive: A2 - Guideline
MSI-H/dMMR MSI-H/dMMR	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	MSI-H/dMMR MSI-H/dMMR	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
RRM1 underexpression RRM1 underexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	RRM1 underexpression RRM1 underexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials	mitotane Sensitive: C3 – Early Trials
TMB-L TMB-L	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TMB-L TMB-L	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials	mitotane Sensitive: C3 – Early Trials
MGMT underexpression MGMT underexpression	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	MGMT underexpression MGMT underexpression	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	temozolomide Sensitive: C3 – Early Trials	temozolomide Sensitive: C3 – Early Trials
TMB-L + PD-L1 underexpression TMB-L + PD-L1 underexpression	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	TMB-L + PD-L1 underexpression TMB-L + PD-L1 underexpression	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials	nivolumab + ipilimumab Sensitive: C3 – Early Trials
MSH2 mutation MSH2 mutation	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	MSH2 mutation MSH2 mutation	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	pembrolizumab Sensitive: C4 – Case Studies	pembrolizumab Sensitive: C4 – Case Studies
SDHB mutation SDHB mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	SDHB mutation SDHB mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	temozolomide Sensitive: C4 – Case Studies	temozolomide Sensitive: C4 – Case Studies
MSH2 mutation + MSH6 mutation MSH2 mutation + MSH6 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	MSH2 mutation + MSH6 mutation MSH2 mutation + MSH6 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	pembrolizumab Sensitive: C4 – Case Studies	pembrolizumab Sensitive: C4 – Case Studies
STK11 mutation STK11 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	STK11 mutation STK11 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	temozolomide + capecitabine Resistant: C4 – Case Studies	temozolomide + capecitabine Resistant: C4 – Case Studies
STK11 mutation STK11 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	STK11 mutation STK11 mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	everolimus Sensitive: C4 – Case Studies	everolimus Sensitive: C4 – Case Studies
ATRX mutation + TP53 mutation + PTEN mutation ATRX mutation + TP53 mutation + PTEN mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	ATRX mutation + TP53 mutation + PTEN mutation ATRX mutation + TP53 mutation + PTEN mutation	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	temozolomide Sensitive: C4 – Case Studies	temozolomide Sensitive: C4 – Case Studies
TMB-H TMB-H	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	TMB-H TMB-H	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	nivolumab + ipilimumab Resistant: C4 – Case Studies	nivolumab + ipilimumab Resistant: C4 – Case Studies
TMB-H TMB-H	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	TMB-H TMB-H	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	temozolomide Resistant: C4 – Case Studies	temozolomide Resistant: C4 – Case Studies
MSH2 deletion + MSH6 deletion MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	MSH2 deletion + MSH6 deletion MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma Pituitary Gland Carcinoma	temozolomide Resistant: C4 – Case Studies	temozolomide Resistant: C4 – Case Studies
FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	FGFR3-TACC3 fusion FGFR3-TACC3 fusion	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	erdafitinib Sensitive: C4 – Case Studies	erdafitinib Sensitive: C4 – Case Studies
TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	rubitecan Sensitive: D – Preclinical	rubitecan Sensitive: D – Preclinical
TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	teniposide Sensitive: D – Preclinical	teniposide Sensitive: D – Preclinical
CDK1 overexpression CDK1 overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	CDK1 overexpression CDK1 overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	DSP-2033 Sensitive: D – Preclinical	DSP-2033 Sensitive: D – Preclinical
CDK4 overexpression CDK4 overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	CDK4 overexpression CDK4 overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	palbociclib Sensitive: D – Preclinical	palbociclib Sensitive: D – Preclinical
TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	etoposide oral Sensitive: D – Preclinical	etoposide oral Sensitive: D – Preclinical
TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	pirarubicin Sensitive: D – Preclinical	pirarubicin Sensitive: D – Preclinical
TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	mitoxantrone Sensitive: D – Preclinical	mitoxantrone Sensitive: D – Preclinical
AURKA overexpression AURKA overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	AURKA overexpression AURKA overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	SA033 + AMG 900 Sensitive: D – Preclinical	SA033 + AMG 900 Sensitive: D – Preclinical
AURKB overexpression AURKB overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	AURKB overexpression AURKB overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	SA033 + AMG 900 Sensitive: D – Preclinical	SA033 + AMG 900 Sensitive: D – Preclinical
TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	idarubicin hydrochloride Sensitive: D – Preclinical	idarubicin hydrochloride Sensitive: D – Preclinical
TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	SA033 Sensitive: D – Preclinical	SA033 Sensitive: D – Preclinical
TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	daunorubicin Sensitive: D – Preclinical	daunorubicin Sensitive: D – Preclinical
TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	TOP2A overexpression TOP2A overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	aclarubicin Sensitive: D – Preclinical	aclarubicin Sensitive: D – Preclinical
AURKB overexpression AURKB overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	AURKB overexpression AURKB overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	mitotane + AMG 900 Sensitive: D – Preclinical	mitotane + AMG 900 Sensitive: D – Preclinical
AURKA overexpression AURKA overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	AURKA overexpression AURKA overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	mitotane + AMG 900 Sensitive: D – Preclinical	mitotane + AMG 900 Sensitive: D – Preclinical
AURKA overexpression AURKA overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	AURKA overexpression AURKA overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	AMG 900 Sensitive: D – Preclinical	AMG 900 Sensitive: D – Preclinical
AURKB overexpression AURKB overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	AURKB overexpression AURKB overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	AMG 900 Sensitive: D – Preclinical	AMG 900 Sensitive: D – Preclinical
MET overexpression MET overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	MET overexpression MET overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	cabozantinib capsule Sensitive: D – Preclinical	cabozantinib capsule Sensitive: D – Preclinical
CDK2 overexpression CDK2 overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	CDK2 overexpression CDK2 overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	DSP-2033 Sensitive: D – Preclinical	DSP-2033 Sensitive: D – Preclinical
EZH2 overexpression EZH2 overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	EZH2 overexpression EZH2 overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	mitotane + EZH2 inhibitor Sensitive: D – Preclinical	mitotane + EZH2 inhibitor Sensitive: D – Preclinical
ASXL1 overexpression ASXL1 overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	ASXL1 overexpression ASXL1 overexpression	Adrenal Cortex Carcinoma Adrenal Cortex Carcinoma	EDP Resistant: D – Preclinical	EDP Resistant: D – Preclinical

Endocrine Cancer

Associations(50)

Associations
(50)